Cargando…
Evolving treatment paradigms for PCV
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD (nAMD) that accounts for a significant proportion of nAMD cases worldwide, and particularly in Asia. Contemporary PCV treatment strategies have closely followed those used in typical nAMD, though there are significant gaps in kn...
Autores principales: | Fenner, Beau J., Cheung, Chui Ming Gemmy, Sim, Shaun S., Lee, Won Ki, Staurenghi, Giovanni, Lai, Timothy Y. Y., Ruamviboonsuk, Paisan, Kokame, Gregg, Yanagi, Yasuo, Teo, Kelvin Y. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807588/ https://www.ncbi.nlm.nih.gov/pubmed/34262165 http://dx.doi.org/10.1038/s41433-021-01688-7 |
Ejemplares similares
-
Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV
por: Vyas, Chinmayi Himanshuroy, et al.
Publicado: (2022) -
COVID-19-Related Retinal Micro-vasculopathy – A Review of Current Evidence
por: Teo, Kelvin YC, et al.
Publicado: (2022) -
Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
por: Vyas, Chinmayi Himanshuroy, et al.
Publicado: (2021) -
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
por: Lim, Tock H., et al.
Publicado: (2020) -
Does COVID-19 infection leave a mark on the retinal vasculature?
por: Sim, Shaun Sebastian, et al.
Publicado: (2021)